Skip to main content
. Author manuscript; available in PMC: 2023 Feb 15.
Published in final edited form as: Biol Psychiatry. 2021 Sep 3;91(4):359–369. doi: 10.1016/j.biopsych.2021.08.021

Table 3.

Characteristics of samples included in the amyloid (top panel) and tau (bottom panel) meta-analysis.

Study Cohort or Institution, Country N Mean age Female AD biomarker Cognitive status Personality Measure
Amyloid
Terracciano et al 2013 BLSA, US 84 72.4 38% Postmortem mixed NEO-PI-Ra
Snitz et al 2015 U. of Pittsburgh, US 92 81.2 49% PET 11C-PiB CN NEO-FFI
Tautvydaite et al 2017 Lausanne U., CH 110 ~70 ~60% CSF CN + MCI NEO-PI-R
Aschenbrenner et al 2020 DIAN, International 304 37.7 58% PET 11C-PiB mixed IPIP-NEOb
Byun et al 2020 KBASE, KR 397 70.5 56% PET 11C-PiB CN + MCI NEO-FFI
Giannakopoulos et al 2020 U. of Geneva, CH 65 74.2 63% PET 18F-Florbetapir CN NEO-PI-Rc
Pichet Binette et al 2020 PREVENT-AD, CA 115 67.6 75% PET [18F]NAV4694 CN BFI
Pichet Binette et al 2020 DIAN, International 117 34.6 55% PET 11C-PiB CN IPIP-NEOb
Schultz et al 2020 WashU, US 128 66.7 61% PET 18FAV-45 CN NEO-FFI
Yoon et al 2020 BACS, US 129 72.1 54% PET 11C-PiB CN BFI
Graham et al 2021 RUSH, US 1375 89.6 68% Postmortem mixed NEOd
Baena et al in press COLBOS, CO 20 35.7 60% PET 11C-PiB CN NEO-FFI
Current study BLSA, US 196 78.6 50% PET 11C-PiB CN NEO-PI-R
Tau
Terracciano et al 2013 BLSA, US 84 72.4 38% Postmortem mixed NEO-PI-Ra
Tautvydaite et al 2017 Lausanne U., CH 110 ~70 ~60% CSF CN + MCI NEO-PI-R
Aschenbrenner et al 2020 DIAN, International 304 37.7 58% CSF mixed IPIP-NEO
Pichet Binette et al 2020 PREVENT-AD, CA 115 67.6 75% PET 18F-flortaucipir CN BFI
Schultz et al 2020 WashU, US 128 66.7 61% PET 18F-flortaucipir CN NEO-FFI
Graham et al 2021 RUSH, US 1375 89.6 68% Postmortem mixed NEOd
Baena et al in press COLBOS, CO 20 35.7 60% PET 18F-flortaucipir CN NEO-FFI
Current study BLSA, US 95 76.9 56% PET 18F-flortaucipir CN NEO-PI-R

Notes. BACS = Berkeley Aging Cohort Study; BLSA = Baltimore Longitudinal Study of Aging; COLBOS = Colombia-Boston Longitudinal Biomarker Study; DIAN = Dominant Inherited Alzheimer Network; KBASE = Korean Brain Aging Study; PREVENT-AD = EValuation of Experimental or Novel Treatments for AD; RUSH = Rush University, Memory and Aging Project and Religious Orders Study; U. = University; WashU = Knight Alzheimer Disease Research Center, Washington University; CA = Canada; CH = Switzerland; CO = Colombia; KR = South Korea; US = United States of America; PET = positron emission tomography; CSF = cerebrospinal fluid; 11C-PiB = 11C Pittsburgh compound B; MCI = Mild cognitive impairment; CN = Cognitively normal; mixed = CN, MCI and/or dementia; IPIP = International Personality Item Pool; BFI = Big Five Inventory; NEO-FFI = NEO-Five Factor Inventory; NEO-PI-R = NEO-Personality Inventory Revised.

a

The BLSA postmortem study (15) included 84 participants for neuroticism, extraversion, and openness and 59 for agreeableness and conscientiousness; there was no overlap between the previous BLSA postmortem (15) and current PET sample.

b

Effect estimates for neuroticism and conscientiousness were from (43) while for extraversion, openness and agreeableness were from (25).

c

Sixty-one 18F-Florbetapir and four 18F-Flutemetamol-PET.

d

Rush ROS participants completed 6 items for Extraversion and 12 for each of the other traits. Openness and agreeableness were not assessed in MAP (16).